THNR Holdings — Amplify Weight Loss Drug & Treatment ETF
All 21 reported holdings of Amplify Weight Loss Drug & Treatment ETF (THNR) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Novo Nordisk A/S | 9.76% | $425.76K |
| Eli Lilly & Co | 9.26% | $404.21K |
| Scholar Rock Holding Corp | 5.71% | $249.21K |
| Hims & Hers Health Inc | 5.57% | $243.14K |
| Viking Therapeutics Inc | 5.49% | $239.60K |
| AbbVie Inc | 5.20% | $226.73K |
| Arrowhead Pharmaceuticals Inc | 5.08% | $221.87K |
| Innovent Biologics Inc | 5.00% | $218.23K |
| Amgen Inc | 4.58% | $199.89K |
| Chugai Pharmaceutical Co Ltd | 4.57% | $199.33K |
| Merck & Co Inc | 4.56% | $199.18K |
| AstraZeneca PLC | 4.56% | $198.91K |
| Roche Holding AG | 4.52% | $197.21K |
| Regeneron Pharmaceuticals Inc | 4.49% | $195.79K |
| CSPC Pharmaceutical Group Ltd | 4.48% | $195.54K |
| Pfizer Inc | 4.39% | $191.60K |
| Zealand Pharma A/S | 3.49% | $152.11K |
| Kailera Therapeutics Inc | 2.46% | $107.15K |
| Jiangsu Hengrui Pharmaceutical | 2.27% | $98.85K |
| Invesco Government & Agency Po | 2.01% | $87.85K |
| Hanmi Pharm Co Ltd | 2.00% | $87.49K |
THNR overview: performance, fees, allocation and SEC filings